Karl Belanger
Overview
Explore the profile of Karl Belanger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
15066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Routy B, Lenehan J, Miller Jr W, Jamal R, Messaoudene M, Daisley B, et al.
Nat Med
. 2023 Nov;
30(2):604.
PMID: 37923839
No abstract available.
2.
Routy B, Lenehan J, Miller Jr W, Jamal R, Messaoudene M, Daisley B, et al.
Nat Med
. 2023 Jul;
29(8):2121-2132.
PMID: 37414899
Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has...
3.
Tonneau M, Nolin-Lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, et al.
Oncoimmunology
. 2022 Jul;
11(1):2096535.
PMID: 35832043
The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated...
4.
Quinones M, Belanger K, Lemieux Blanchard E, Lemieux B, Bahary J, Masucci L, et al.
Curr Oncol
. 2021 Aug;
28(4):3104-3114.
PMID: 34436037
Medulloblastoma is an aggressive primary brain tumor that is extremely rare in adults; therefore, prospective studies are limited. We reviewed the information of all MB patients treated at the CHUM...
5.
Taillefer V, Pigeon M, Chen M, Larochelle C, Florescu M, Belanger K, et al.
J Oncol Pharm Pract
. 2020 Feb;
26(6):1538-1543.
PMID: 32063105
Introduction: Nivolumab is a programmed death 1 (PD-1) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of eight different cancers including metastatic melanoma. Immune checkpoint blockade...
6.
LaPointe S, Florescu M, Nguyen D, Djeffal C, Belanger K
Neurooncol Pract
. 2019 Aug;
2(4):192-198.
PMID: 31386083
Background: The American Academy of Neurology (AAN) does not recommend routine use of prophylactic antiepileptic drugs (pAEDs) in patients with newly diagnosed brain tumors. If used in the perioperative setting,...
7.
Demuth S, Lasry D, Obaid S, Letourneau-Guillon L, Chasse M, Belanger K, et al.
Can J Neurol Sci
. 2019 Jun;
46(5):642-644.
PMID: 31232240
No abstract available.
8.
Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al.
Oncoimmunology
. 2019 Mar;
8(4):e1568812.
PMID: 30906663
: The gut microbiota has been shown to be an important determinant of the efficacy of immune checkpoint inhibitions (ICI) in cancer. Several lines of evidence suggest that antibiotic (ATB)...
9.
Jamal R, Lapointe R, Cocolakis E, Thebault P, Kazemi S, Friedmann J, et al.
J Immunother Cancer
. 2017 Nov;
5(1):83.
PMID: 29157311
Background: Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit from...
10.
Chennouf A, Arslanian E, Roberge D, Berthelet F, Bojanowski M, Bahary J, et al.
Cureus
. 2017 Apr;
9(3):e1068.
PMID: 28409069
Inflammatory myofibroblastic tumors (IMT) of the central nervous system (CNS) are rare entities that have a predilection for local recurrences. Approximately half of the inflammatory myofibroblastic tumors contain translocations that...